LAS VEGAS, NV / ACCESSWIRE / September 22, 2015 / Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, en route to finding companies with the best potential. Our main sectors of interest include technology, and biotech companies.
There’s no doubt the past couple weeks have been a little scary for investors with market volatility causing massive swings in the market causing some investors to run for the hills. While caution is warranted in times like these, it is worth noting that the Biotech industry is minimally affected by China’s economy and the beleaguered commodities complex (except for oil recently). The effect is even less significant with smaller companies whose survival hinges on early-stage clinical trial results.
A brief look at the iShares Nasdaq Biotechnology index shows biotechs are up 13% for 2015. Well ahead of the broader market. However, the index is down 15% from its July high so therefore we believe this presents many interesting buying opportunities in the market.
With that said, these 4 biotechnology stocks could offer you some excellent opportunities to beat the market:
1. Propanc Health Group (PPCH). Propanc is a cancer (oncology) focused biotech developing potential pharmaceuticals for the treatment of colorectal and pancreatic cancer. PPCH has been on a tear in 2015. Retail investors have realized massive profits trading PPCH which has seen gains of 13,000%. The stock has run from $0.001 to a high of $0.134. If you could have timed the trade from its bottom to the top you could’ve turned $8,000 into $1 Million+.
Propanc (PPCH) is now well of its highs, and there is reason to believe the stock is poised to make a run back to the 52 week high. They are currently completing their pre-clinical animal efficacy studies which will then be used to meet with the regulatory agencies to agree on the development pathway for PRP to start pivotal animal toxicology studies in preparation for clinical trials. The Company has recently released positive news regarding tumor shrinkage in mice which largely went unnoticed because of the slow trading in the summer months. As the animal studies unfold, the Company should continually release news as they mentioned they would in their recent press releases.
The Company mentioned in a recent PR that they are moving to the full-scale studies from the initial pilot studies; more positive news could trigger another big run for PPCH investors.
If Propanc’s drug (PRP) gets into clinical trials (within 1 year), and then licensed to Big Pharma (2 years total potentially, provided everything goes as planned) the market for pancreatic and colorectal cancer is enormous, where deals are valued into the hundreds of millions, if not billions of dollars. There are no real effective medications to help in the fight of pancreatic cancer, and if you’ve ever known someone to have this aggressive killer, you know its devastating effects. The current front-line medication for pancreatic cancer patients, on average, extends life by only 1-2 months – not that impressive – we need alternatives.
2. Advaxis Inc. (ADXS). ADXS is another biotech darling that made a 1,105% move over the past year from $2.50 to $30.13. The stock has since come down 50% from its high, but is still up 444% from the low. Its current position on the chart offers an interesting entry opportunity for investors.
ADXS is a clinical-stage biotechnology company developing cancer immunotherapies, they recently announced that final clinical data from Stage 1 of the ongoing two-stage Phase 2 study (GOG-0265) of Advaxis’s lead LmTechnology(TM) immunotherapy, axalimogene filolisbac (ADXS-HPV), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), will be presented at the American Gynecological & Obstetrical Society (AGOS) annual meeting in Half Moon Bay, Calif. by Tom Hertzog, M.D., Clinical Director at the University of Cincinnati Cancer Institute, on September 17, 2015, at 11:15 a.m. PDT. Activity in the stock could pick up heading into next week’s meeting, and may be a catalyst moving Advaxis back toward its highs.
3. Aquinox Pharmaceuticals, Inc. (AQXP). Continuing the theme of big winners experiencing a pullback, Aquinox moved to $55.75 from $1.38 this year. Currently sitting 70% off the highs AQXP is another opportunity for biotech investors to capitalize on this market dip. The company has seen growth driven by positive results from second phase testing of its drug AQX-1125. As per the 2Q15 earnings report, the company’s net income has gone up by 25.9% as compared to the 1Q15 earnings of 20.76%.
According to the Market Realist “the company can increase their PE and EPS by achieving their break-even level, which also helps the company in expanding itself and increasing its profit. Aquinox has a positive future outlook and will likely continue to better its performance in the near future.”
4. Spectrum Pharmaceuticals, Inc. (SPPI)- Unlike the other 3 stocks mentioned, SPPI hasn’t seen a massive run, yet. However, much like the other biotechs we’re highlighting in this article, the company has come off their highs which they originally reached at the apex of a nice move which started in May. After pulling back 25% it looks like SPPI may be presenting investors a great entry opportunity.
Spectrum, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, recently announced that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Rodman & Renshaw 17th Annual Global Investment Conference being held at the St. Regis Hotel in New York City. The Company presentation is on Thursday, September 10, 2015, at 9:35 AM ET. The stock could see some interest on the heels of this presentation.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For this press release ACR Communication, LLC. was compensated $2,000 by Regal Consulting, LLC. on behalf of Propanc Health Group, Corp.
Contact:
Acrlasvegas@gmail.com
SOURCE: ACR Communication, LLC
ReleaseID: 432143
